Welcome to the Biomarkers and Renal Patients in COVID-19 (BRIC) study

We are exploring the impact of COVID-19 on renal patients who require renal replacement therapy: haemodialysis, peritoneal dialysis, renal transplantation.

The BRIC Study: Understanding the impact of COVID-19 on renal patients

The coronavirus SARS-CoV2 pandemic is a major challenge for patients with renal impairment and immunosuppression. Understanding how renal patients respond to COVID-19 and how we can improve clinical management will be vital to optimising care and protecting these patients.

We have established this universal, collaborative registry to collect anonymised data  of patients with end-stage renal failure/disease and who develop laboratory-confirmed COVID-19. We encourage reports from worldwide. Wherever you are, we want to hear from you.Your clinical experience with these patients is important.

Reporting a case takes around 5 minutes. We are pleased to acknowledge all those who contribute in any publication and we will invite major contributors to join our authorship.

The aims of the BRIC study are:

  • Assessment of characteristics of end-stage renal failure/disease patients with COVID-19 in association with outcome
  • Assessment of renal replacement therapy of renal patients during COVID-19 infection to compare this with gold-standard therapy
  • Inform the renal and transplant communities with regards to prognosis of COVID-19 in their patients
  • Identify biological and immunological factors that will guide future therapeutic research and which may predict risk from COVID-19 in these patient cohorts

The BRIC registry:

As a retrospective registry which does not use patient-identifiable data, the BRIC registry does not require formal ethical approval or NHS ethics. The BRIC registry uses Project REDcap, a secure data collection system which is hosted by the Medical Sciences Division at the University of Oxford. The BRIC database falls out of the definition of a research project as defined by the Health Research Authority (HRA). Read more about this here.

Biological samples are also being collected as part of the BRIC study, from consenting renal patients with COVID-19 within the Oxford University Hospitals NHS Foundation Trust. As this part of the study requires patient samples, it has undergone formal ethical approval under the national ISARIC study (South Central – Oxford C REC 13/SC/0149).

Copyright Bricstudy 2020